Buy the Dip Now: 3 Cannabis Stocks

Buy small-cap weed stocks Village Farms International Inc. (TSX:VFF)(NASDAQ:VFF), MediPharm Labs Corp. (TSX:LABS), and The Supreme Cannabis Company Inc. (TSX:FIRE) to form a solid marijuana stock portfolio.

| More on:
Cannabis stocks have fallen.
You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

The share prices of three small-cap weed stocks are falling. Village Farms (TSX:VFF)(NASDAQ:VFF), MediPharm (TSX:LABS), and Supreme Cannabis (TSX:FIRE) are the weed stocks you should buy now for overflowing gains in the future.

Top greenhouse grower

Village Farms is one of the longest longest-operating vertically integrated greenhouse growers in North America and the only publicly-listed greenhouse produce company on the TSX.

The company is creating inroads in Canada’s two provinces whose combined population composes 50% of the country’s total population. Its Pure Sunfarms struck supply agreements with British Columbia Liquor Distribution Branch (BCLDB) and Ontario Cannabis Retail Corporation (OCRC).

Pure SunFarms is the joint venture for large-scale, low-cost, high-quality cannabis production that Village Farms own 50%. It would supply BCLDB and OCRC with PureSunfarms’ branded cannabis products for the recreational market. Discussions are ongoing with other provinces to strike more supply agreements.

Analysts are bullish about the prospects of VFF, forecasting the stock to gain at least 108%, from $14.44 to $30.07 in the next 12 months. With the industry entering a new phase amid the legalization of hemp-derived CBD, VFF’s value could even triple.

Pioneer in extraction

The allure of MediPharm as a viable weed stock would undoubtedly rise in the coming months. Many cannabis companies are preparing to compete in the lucrative derivative market. But to produce high-quality products, you need an expert to extract cannabinoids (CBD) from cannabis and hemp biomass.

MediPharm is already producing and selling pharma-grade cannabis oil and concentrates for derivative products in Australia and Canada. But it could also provide contract processing services to other licensed producers and growers of cannabis.

The annual run-rate processing capacity of this $608.5 million company 500,000 kilos but its expansion is ongoing. As MediPharm signs up more clients, the company would be awash with cash from its contracts. Profitability is 100% certain in the foreseeable future.

Analysts covering MediPharm are maintaining their buy ratings. A price below $5 is a steal for this weed stock that offers minimal risk.  Among its significant clients are Canopy Growth, Cronos Group, and equally hot weed stock Supreme Cannabis.

Premium quality products

FIRE is another weed stock that carries a “strong buy” rating. In its fiscal Q4 2019 report, the company was able to finally achieve its first positive adjusted EBITDA ($3.2 million). For the quarter, FIRE’s net revenue is $19 million or a 90% increase from Q3 2019.

The company’s total revenue in fiscal 2019 is $41.8 million, which represents a remarkable 370% jump from the $8.9 million total revenue posted in fiscal 2018. Management expects total net revenue in fiscal 2020 to be around $150 million to $180 million.

FIRE is the weed stock to watch. The company aims to have the best-in-class infrastructure. With a host of top consumer brands, FIRE would make a huge impact on the international markets.

Standouts

Make no mistake. Village Farms, MediPharm, and Supreme Cannabis, would outperform and be more profitable than the larger industry peers.  The weed stocks are must-haves if you want to build the safest marijuana stock portfolio.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of Village Farms International, Inc.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »